A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
Conditions
Interventions
- DRUG: Molnupiravir 200 mg
Sponsor
University of Witwatersrand, South Africa
Collaborators